AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.
AstraZeneca Announces Symbicort Is Now Available In The U.S. U.S. Asthma Sufferers Now Have a New Choice of Combination Therapy to Help Achieve Asthma Control LONDON ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback